durvalumab,sorafenib,tremelimumab
pfizer,astrazeneca
['hcc', 'himalaya']
four year os of himalaya - stride 48 mo os 25.2% in those achieving control 36.2% at 4 years impressive benchmarks and great presentation #brunosangro #wcgic2023 #hcc 
Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦